CME vs SPGI Stock Comparison: Q4 Earnings Preview as Trading Volumes Meet Data Demand

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CME turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 24 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.

CME moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CME crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 46%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 41%.

The Aroon Indicator for CME entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 57 cases where CME's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 51%.

The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on CME as a result. In 64 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.

Following a +2.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 176 of 346 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

CME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock slightly better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.569) is normal, around the industry mean (-5.093). P/E Ratio (22.327) is within average values for comparable stocks, (25.252). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). CME has a moderately high Dividend Yield (0.043) as compared to the industry average of (0.018). CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).